Synthesis of aza-analogues of Ganciclovir

Tetrahedron

Volumn 62, Issue 44, 2006, Pages 10325-10331

  Koszytkowska Stawińska, Mariola ^a   Sas, Wojciech ^a   De Clercq, Erik ^b  

^a WARSAW UNIVERSITY OF TECHNOLOGY   (Poland)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Acyclic azanucleosides; Ganciclovir analogues; N Mesyl 5 hydroxymethyl 1,3 oxazolidine; N Pivaloyloxymethyl sulfonamides

Indexed keywords

1 [N [2 BENZOYLOXY 1 (HYDROXYMETHYL)ETHYL]MESYLAMINOMETHYL] 5 FLUORO 1H,3H PYRIMIDIN 2,4 DIONE; 1 [N [2 BENZOYLOXY 1 (HYDROXYMETHYL)ETHYL]MESYLAMINOMETHYL] 5 METHYL 1H,3H PYRIMIDIN 2,4 DIONE; 1 [N [2 HYDROXY 1 (HYDROXYMETHYL)ETHYL]MESYLAMINOMETHYL] 5 FLUORO 1H,3H PYRIMIDIN 2,4 DIONE; 1 [N [2 HYDROXY 1 (HYDROXYMETHYL)ETHYL]MESYLAMINOMETHYL] 5 METHYL 1H,3H PYRIMIDIN 2,4 DIONE; 4 (BENZOYLAMINO) 1 [N [2 BENZOYLOXY 1 (HYDROXYMETHYL)ETHYL] MESYLAMINOMETHYL] 1H PYRIMIDIN 2 ONE; 5 (2 BROMOVINYL) 2' DEOXYURIDINE; 6 (BENZOYLAMINO) 9 [N [2 BENZOYLOXY 1 (HYDROXYMETHYL)ETHYL] MESYLAMINOMETHYL] 9H PURINE; 9 (2,3 DIHYDROXYPROPYL)ADENINE; ACICLOVIR; ANTIVIRUS AGENT; GANCICLOVIR; GANCICLOVIR DERIVATIVE; NUCLEOSIDE DERIVATIVE; RIBAVIRIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CATALYSIS; CATALYST; CONTROLLED STUDY; COXSACKIE VIRUS B4; DRUG SYNTHESIS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; IC 50; NONHUMAN; PARAINFLUENZA VIRUS 3; PRIORITY JOURNAL; REACTION ANALYSIS; REOVIRUS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SINDBIS VIRUS; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS;

EID: 33748688602     PISSN: 00404020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tet.2006.08.072     Document Type: Article

References (47)

1. El Ashry E.S.H., and El Kilany Y. Adv. Heterocycl. Chem. 67 (1997) 391-438
2. El Ashry E.S.H., and El Kilany Y. Adv. Heterocycl. Chem. 68 (1997) 1-88
3. El Ashry E.S.H., and El Kilany Y. Adv. Heterocycl. Chem. 69 (1998) 129-215
4. Gao H., and Mitra A.K. Synthesis (2000) 329-351
5. De Clercq E. J. Clin. Virol. 30 (2004) 115-133
6. Galmarini C.M., Mackey J.R., and Dumontet C. Lancet Oncol. 3 (2002) 415-424
7. Anastasi C., Quéléver G., Burlet S., Garino C., Souard F., and Kraus J.-L. Curr. Med. Chem. 10 (2003) 1825-1843
8. Calogeropoulou T., Detsi A., Lekkas E., and Koufaki M. Curr. Top. Med. Chem. 3 (2003) 1467-1495
9. De Clercq E., and Field H.J. Br. J. Pharmacol. 147 (2006) 1-11
10. Montgomery J.A., and Temple C. J. Am. Chem. Soc. 83 (1961) 630-635
11. Nishitani T., Iwasaki T., Mushika Y., Inoue I., and Miyoshi M. Chem. Pharm. Bull. 28 (1980) 1137-1141
12. Nishitani T., Horikawa H., Iwasaki T., Matsumoto K., Inoue I., and Miyoshi M. J. Org. Chem. 47 (1982) 1706-1712
13. Inoue, K.; Iwasaki, T.; Nishitani, T.; Kondou, K.; Arai, Y. JP58216169, 1983;
14. Chem. Abstr. 100 (1984) 174851b
15. Miyoshi, S.; Inoue, K.; Mushishika, Y.; Iwasaki, T.; Nishitani, T.; Arai, Y. JP58213762, 1983;
16. Chem. Abstr. 100 (1984) 174852c
17. Kingsbury, W. D.; Boehm, J. C.; Mehta, R. J.; Grappel, S. F.; Gilvarg, C. J. Med. Chem. 1984, 27, 1447-1451;
18. Sergeev V.N., Shapovalenko E.P., and Baukov Yu.I. Zh. Obshch. Khim. 57 (1987) 1315-1321
19. Russ. J. Gen. Chem. (Engl. Transl.) 57 (1987) 1177-1182
20. Zheltonogova E.A., Oleneva G.I., Shapovalenko E.P., Belavin I.Yu., Shipov A.G., and Baukov Yu.I. Zh. Obshch. Khim. 60 (1990) 1390-1394
21. Russ. J. Gen. Chem. (Engl. Transl.) 60 (1990) 1245-1249
22. Khutova B.M., Klyuchko S.V., and Prikazchikova L.P. Khim. Geterotsikl. Soedin. (1991) 512-515
23. Chem. Heterocycl. Compd. (Engl. Transl.) 27 (1991) 407-409
24. Kita Y., Shibata N., Yoshida N., and Takashi T. Chem. Pharm. Bull. 40 (1992) 1733-1736
25. Nichifor M., and Schacht E.H. Tetrahedron 50 (1994) 3747-3760
26. Besova E.A., Goloshchapov N.M., Goloshchapova E.N., Michurina A.E., Shipov A.G., and Baukov Yu.I. Zh. Obshch. Khim. 68 (1998) 502-504
27. Russ. J. Gen. Chem. (Engl. Transl.) (1998) 469-471
28. Madec-Lougerstay R., Florent J.-C., and Monneret C. J. Chem. Soc., Perkin Trans. 1 (1999) 1369-1376
29. Gilchrist T.L., and Mendonca R. Synlett (2000) 1843-1845
30. 1 no acyclic azanucleoside is described.
31. Bergmeier S.C., Fundy S.L., and Drach J.C. Nucleosides Nucleotides Nucleic Acids 18 (1999) 227-238
32. Sheikha G.A., La Colla P., and Loi A.G. Nucleosides Nucleotides Nucleic Acids 10 (2002) 619-635
33. Koszytkowska-Stawińska M., and Sas W. Tetrahedron Lett. 45 (2004) 5437-5440
34. Sas, W.; Koszytkowska-Stawińska, M.; Kaleta, K.; De Clercq, E. Nucleosides Nucleotides Nucleic Acids, in press.
35. Literature data show that the synthesis of N-unprotected acyclic azanucleosides is impossible; it was found out that attempts at removal of N-acyl protecting group from 'cyclic' azanucleosides caused their rapid decomposition. Altmann K.-H. Tetrahedron Lett. 34 (1993) 7721-7724
36. Rassau G., Pinna L., Spanu P., Ulgheri F., Casiraghi G., and Altmann K.-H. Tetrahedron Lett. 35 (1994) 4019-4022
37. Recently, similar observation has been made by us for acyclic N-acetyl analogues of ganciclovir; an intramolecular migration of N-acetyl group from nitrogen atom to oxygen, causing deprotection of the nitrogen atom of sugar mimic, is responsible for a decomposition of the azanucleosides in a basic medium (unpublished results).
38. Koszytkowska-Stawińska M., Sas W., and Sowińska A. J. Chem. Res. (S) (1996) 162-163
39. Vorbrüggen H., and Ruh-Pohlenz C. Handbook of Nucleoside Synthesis (2001), Wiley, New York, NY Tables I-XI, pp 110-589
40. Gassman P.G., Burns S.J., and Pfister K.B. J. Org. Chem. 58 (1993) 1449-1457
41. Lopes F., Moreira R., and Iley J. Bioorg. Med. Chem. 8 (2000) 707-716
42. Zou R., and Robins M.J. Can. J. Chem. 65 (1987) 1436-1437
43. Robins M.J., Zou R., Guo Z., and Wnuk S.F. J. Org. Chem. 61 (1996) 9207-9212
44. Tolle-Sander S., Lentz K.A., Maeda D.Y., Coop A., and Polli J.E. Mol. Pharmacol. 1 (2004) 40-48
45. 10 acyclic aza-analogues of guanosine as well as adenosine (independently of kind of N-substituent), the fiasco of preparation of the N-mesyl analogue guanosine by various methods (Ref. 9 and this paper) is somewhat puzzling, indeed. Studies on solution of this problem are in progress.
46. Required to cause a microscopically detectable alteration of normal cell morphology.
47. 6SM cells, >100 μM).